Detailed Information

Cited 5 time in webofscience Cited 8 time in scopus
Metadata Downloads

Enfortumab vedotin-related pneumonitis is more common than expected and could lead to acute respiratory failure

Authors
Yoon, ShinkyoShin, Sang JoonKim, Ho CheolKim, Young SaingLee, Hyo JinKeam, BhumsukChoi, Yoon JiKim, Yu JungPark, InkeunPark, Se HoonLee, Jae Lyun
Issue Date
Oct-2022
Publisher
Pergamon Press Ltd.
Keywords
Urothelial carcinoma; Enfortumab vedotin; Pneumonitis
Citation
European Journal of Cancer, v.174, pp 81 - 89
Pages
9
Indexed
SCIE
SCOPUS
Journal Title
European Journal of Cancer
Volume
174
Start Page
81
End Page
89
URI
https://scholarworks.korea.ac.kr/kumedicine/handle/2021.sw.kumedicine/61883
DOI
10.1016/j.ejca.2022.07.014
ISSN
0959-8049
1879-0852
Abstract
Purpose To analyse the incidence of pneumonitis related to enfortumab vedotin (EV) in patients with metastatic urothelial cell carcinoma (mUC). Methods Patients with mUC who participated in two EV clinical trials in South Korea were analysed for the incidence and clinical course of EV-related pneumonitis through retrospective, independent review. The clinical characteristics and radiologic attributes of potential pneumonitis were identified and reviewed by the participating investigators and pulmonologists. Results Between October 2018 and January 2020, 64 patients were enrolled in the EV-201 and EV-301 trials across eight institutions in South Korea and were treated with EV. Among them, 18 (28.1%) developed all-grade EV-related pneumonitis, from which 2 (11.1%) patients died. The median time between the last dosing of immunotherapy and the start of EV was 5.6 weeks (range, 0.71–143.1). The median time from the start of EV treatment to the onset of pneumonitis was 13 weeks (range, 2.7–51.0). Of the patients who developed pneumonitis, 7 (38.9%) were clinically asymptomatic. The most common radiologic finding was organising pneumonia (66.7%). Conclusions Although we could not rule out the relationship with prior immunotherapy administration, EV-related pneumonitis occurred in approximately 25% of the patients who had received EV in two prospective clinical trials, from which two died. Clinicians should closely monitor patients who have experienced immunotherapy treatment failure for the development of pneumonitis. A delay between initiating EV after termination of immunotherapy should be considered with caution.
Files in This Item
There are no files associated with this item.
Appears in
Collections
2. Clinical Science > Department of Medical Oncology and Hematology > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Choi, Yoon Ji photo

Choi, Yoon Ji
Anam Hospital (Department of Medical Oncology and Hematology, Anam Hospital)
Read more

Altmetrics

Total Views & Downloads

BROWSE